Combining conventional therapy with immunotherapy: A risky business?

Eur J Cancer 2019 May 6;113:41-44. Epub 2019 Apr 6.

Department of Gynaecology and Obstetrics, Leuven Cancer Institute, UZ Leuven, Leuven, Belgium; Department of Oncology, Laboratory of Tumour Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium; Department of Oncology, Laboratory of Gynecologic Oncology, KU Leuven, Leuven, Belgium. Electronic address:

Because of the failure of immunotherapy as single agent in a number of cancers, current clinical trials are focusing on combining immunotherapy with other therapies. The most frequently chosen combination for immunotherapy is chemotherapy. However, almost no preclinical data on this combination is available. Some studies even showed a dismal effect of combining chemotherapy with immunotherapy. Taken into account that each of the therapies chosen in a combination will influence the cancer cells but also immune effector cells as well as immunosuppressive cells, and that these three partners will also interact with each other, launching a combination to the patient without proper immune monitoring and preclinical evidence might be devastating.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.02.014DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
May 2019

Publication Analysis

Top Keywords

chosen combination
8
immunotherapy
5
therapies chosen
4
account therapies
4
immunotherapy account
4
combination will
4
will influence
4
influence cancer
4
chemotherapy immunotherapy
4
cancer cells
4
combining chemotherapy
4
chemotherapy preclinical
4
immunotherapy chemotherapy
4
combination immunotherapy
4
preclinical data
4
data combination
4
dismal combining
4
studies dismal
4
cells immune
4
effector cells
4

Similar Publications